RCT | Perioperative nivolumab plus chemotherapy increases pathological response vs. chemotherapy alone in stage III NSCLC

Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Addition of Neoadjuvant Nivolumab to Platinum-Based Chemotherapy in Stage III NSCLC – The ASCO Post

Commentary on Twitter

Original Article: Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer https://t.co/DCcs0tkyPN #oncology pic.twitter.com/0zG9SUbqQj

— NEJM (@NEJM) June 30, 2023